Amgen Inc.

Amgen Fremont Inc.

Medimmune Limited

Warner-Lambert Company

Other

Astrazeneca Ab

Immatics Biotechnologies Gmbh

Curagen Corporation

Amgen Research (Munich) Gmbh

Dendreon Corporation

Celldex Therapeutics Limited

Abgenix, Inc.

Medlmmune Limited

Ian Nevin Foltz

Chadwick Terence King

Jaspal Singh Kang

Orit Foord

Vahe Bedian

Scott L Klakamp

Palaniswami Rathanaswami

Jean M Gudas

Bruce Alan Keyt

Zhulun Wang

Xiao Feng

Larry L Green

Xiao-Chi Jia

Randal Robert Ketchem

Taruna Arora

Qiaojuan Jane Su

Xiaoshan Min

Xiao Dong Yang

Ying Liu

Richard F Weber

Robert Raya

Donghui Shi

Yang Li

Jose Corvalan

Shaw-Fen Sylvia Hu

Ai Ching Lim

Neeraj Jagdish Agrawal

Mary Haak-Frendscho

Gunasekaran Kannan

Joseph Edwin Low

Madhav Narasimha Devalaraja

Kathy Manchulenko

James Leslie Mobley

Laura Sekirov

Hailing Hsu

Frederick W Jacobsen

Dirk E Smith

Rutilio Clark

Michael R Comeau

Junming Yie

Scott A Hammond

Michelle Morrow

Darren L Bates

Melanie Boyle

Matthieu Chodorge

Marat Alimzhanov

Christophe Queva

Kathleen Ann Mulgrew

Francine Zhifen Chen

Murielle M Veniant-Ellison

Sirid-Aimee Kellermann

David Jenkins

Christopher Murawsky

Ross Anthony Stewart

David J Lloyd

Sirid-Aimée Kellermann

Marissa Mock

Jinghong Wang

John Babcock

Glenn N Sivits, Jr

Renee Komorowski

Brandon C P Clavette

Shu-yin Ho

Li Erran Li

John Stephen Babcook

Michael Gallo

Gregory M Landes

Peter S Mezes

Xiao-Dong Yang

Giorgio Senaldi

Marc A Gavin

Dong Xia

David Charles Blakey

Michael Jeffers

Raffaella Faggioni

Gadi Gazit-Bornstein

Jennitte LeAnn Stevens

Susan Ann Cartlidge

Simon Thomas Barry

Kiran Ahluwalia

Naomi Laing

Jose R F Corvalan

Susie Miki Harris

Jianying Dong

Binyam Bezabeh

Sue Ann Cartlidge

Kam Fai Tse

Tobias Raum

Jeonghoon Sun

Edwin L Madison

Christopher Mehlin

Derek Evan Piper

Mark Leo Michaels

Jason Charles O'Neill

Johannes Brozy

Irwin Chen

Yannick Bulliard

Sharon Wong-Madden

Markus Muenz

Mehdi Mesri

The present invention relates to antibody constructs comprising a domain which binds to a MAGEB2 peptide complexed with an HLA and optionally, another domain which binds to CD3. Moreover, the invention provides polynucleotides encoding the antibody constructs, vectors comprising said polynucleotides and host cells transformed or transfected with said polynucleotides or vectors. Furthermore, the invention provides processes for producing the antibody constructs of the invention, medical uses of said antibody constructs, and kits comprising said antibody constructs.

MAGEB2 binding constructs

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)

The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof

Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

Interleukin-2 muteins for the expansion of T-regulatory cells

Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

ST2 antigen binding proteins

Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.

TIGIT and CD112R blockade

Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.

Interleukin-21 mutein/ anti-PD-1 antibody conjugates

Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.

Anti-PD-1 antibodies and methods of treatment

Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.

Targeted binding agents against B7-H1

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing &#x3b2;-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising &#x3b2;-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.

Antigen binding proteins that bind to a complex comprising &#x3b2;-Klotho and an FGF receptor

The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.

Anti-human TREM2 antibodies and uses thereof

Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

Growing community of inventors

Burnaby, Canada

Ian Nevin Foltz